Toujeo Doublestar/Solostar Prefilled Pen (Insulin Glargine U-300)

Insulin glargine U-300 is a long-acting (basal) insulin used to help control blood glucose in diabetes, delivered as a prefilled pen for subcutaneous injection. This page explains the Toujeo Doublestar/Solostar Prefilled Pen in practical terms, including how it works, label-level dosing concepts, storage, and key safety considerations. Ships from Canada to US access may be available through a cash-pay model for people managing prescriptions, including those without insurance.

What Toujeo Doublestar/Solostar Prefilled Pen Is and How It Works

This medicine contains insulin glargine, a basal insulin analog (a modified insulin designed for steady, long action). It forms a depot under the skin and is released slowly to help lower glucose between meals and overnight. Dispensing is completed by licensed Canadian pharmacies after referral review.

Because it is a concentrated formulation (U-300, meaning 300 units/mL), it is not interchangeable with U-100 insulin glargine on a unit-to-unit basis without clinical oversight. US delivery from Canada requests are supported through a prescription referral process, and the product supplied depends on what your prescription specifies and what is available from the dispensing pharmacy. For background context on insulin glargine and Toujeo-specific questions, the site’s What Is Toujeo Insulin guide is a useful companion read.

On CanadianInsulin, related options can be explored by browsing hubs such as Long Acting Insulin and Insulin Medications. These category pages list comparable therapies and devices without replacing your prescriber’s plan.

Who It’s For

Insulin glargine U-300 is used to improve glycemic control in people with diabetes. It may be prescribed for type 1 diabetes in combination with mealtime insulin, or for type 2 diabetes alone or with other glucose-lowering medicines. Indications and age ranges can differ by country labeling, so the package insert supplied with the dispensed product is the reference for approved use.

Contraindications generally include hypersensitivity to insulin glargine or any component of the formulation, and it should not be started during episodes of hypoglycemia (low blood sugar). The Toujeo Doublestar/Solostar Prefilled Pen is not used for diabetic ketoacidosis (DKA) treatment and is not intended for intravenous use or insulin pumps. Condition overviews and related resources are grouped in browseable hubs such as Type 1 Diabetes and Type 2 Diabetes.

People with changing insulin needs (such as acute illness, shifts in eating patterns, renal or hepatic impairment, or steroid use) often require closer monitoring and prescriber input. Any adjustment should follow clinical direction and the product’s labeling rather than self-directed changes.

Dosage and Usage

Basal insulin dosing is individualized. For many patients, insulin glargine U-300 is used once daily at the same time each day, with dose selection based on glucose monitoring and overall treatment goals. The Toujeo Doublestar/Solostar Prefilled Pen should be used exactly as prescribed, and switching from another basal insulin typically requires careful conversion and follow-up because concentrations and release profiles differ.

General pen-use principles apply: confirm the label and expiration date, attach a new needle as directed by the manufacturer, and follow the priming and injection instructions in the device leaflet. Injection sites are rotated within the recommended areas to reduce lipodystrophy (fat or scar changes under the skin) and to support more predictable absorption. Used needles and sharps should be disposed of in an appropriate container per local guidance.

Quick tip: Keep a consistent routine for pen checks (label, clarity, expiry) before each use.

If a dose is missed, the safe response depends on timing, other insulin use, and current glucose readings. The prescribing clinician and the official labeling provide the correct instructions for missed doses and for managing sick days.

Strengths and Forms

This product is supplied as a prefilled insulin pen containing insulin glargine U-300 (Toujeo 300 units/mL). Device variants referenced in prescribing and pharmacy supply chains can include SoloStar or DoubleStar-type injectors, and the exact pen mechanism may differ by market. The Toujeo Doublestar/Solostar Prefilled Pen label and the dispensing pharmacy’s documentation describe the specific device, including dialing increments and maximum deliverable units per injection.

Cartridge volume can also vary by presentation (for example, some markets use smaller or larger mL fills), and outer packaging configurations may differ. Availability is not guaranteed and may change over time based on manufacturer distribution and pharmacy sourcing, so the dispensed form is ultimately determined by prescription details and what a licensed pharmacy can provide.

If you are comparing pen formats and day-to-day handling, device-focused reading such as Lantus SoloStar Insulin Pen can help explain common pen features (dose window, priming, and storage practices) that apply across many basal insulin pens.

Storage and Travel Basics

Unopened insulin is typically stored refrigerated at 2–8°C and protected from light; it should not be frozen. Once a pen is in use, labeling commonly allows storage at room temperature (within specified limits) for a defined in-use period, after which any remaining insulin should be discarded even if it looks normal. The Toujeo Doublestar/Solostar Prefilled Pen that is dispensed should be stored according to its included instructions, since allowable temperatures and in-use days can vary by region and presentation.

For travel, keep insulin with you rather than in checked baggage, and avoid direct contact with ice packs that could freeze the pen. Temperature exposure is a practical safety issue: heat can reduce potency, and freezing can damage the formulation. If you use a cooler, a barrier layer (cloth or sleeve) helps prevent accidental freezing next to cold sources.

Why it matters: Insulin that has been overheated or frozen may not work as expected.

Inspect the solution before use if the product labeling recommends it, and follow the manufacturer’s guidance about drops, cracks, or suspected device damage. If there is any concern about integrity, the safest next step is to consult the dispensing pharmacy and the prescribing clinician for replacement and dosing guidance.

Side Effects and Safety

The most important risk with any insulin therapy is hypoglycemia, which can range from mild symptoms (sweating, shakiness, hunger) to severe events (confusion, seizure, loss of consciousness). Other possible effects include injection-site reactions, itching or rash, edema (swelling), and weight change. Severe allergic reactions are uncommon but require urgent medical care. When required, prescriptions are verified directly with the prescriber.

Concentrated insulins add an additional safety layer: mix-ups between U-300 and U-100 products can lead to dosing errors. Keeping only one basal insulin pen type in active use at a time, and storing different insulins separately, can reduce confusion. Glucose monitoring frequency and targets are individualized, and more frequent checks may be recommended when starting therapy, changing doses, changing other diabetes medicines, or during illness.

Insulin requirements can change with renal impairment, liver disease, changes in physical activity, or dietary patterns. Alcohol can also affect glucose levels and symptom awareness. Any episode of severe hypoglycemia, unexplained hyperglycemia, or repeated nocturnal lows should be discussed with the clinician managing the regimen.

Drug Interactions and Cautions

Many medicines can alter insulin needs by changing glucose production, insulin sensitivity, or appetite. Some glucose-lowering agents may increase the risk of hypoglycemia when used with basal insulin, while other drugs can raise blood sugar and prompt prescriber-led dose adjustments. Beta blockers may blunt some warning signs of hypoglycemia (such as tremor or palpitations), making monitoring and education more important.

Thiazolidinediones (such as pioglitazone or rosiglitazone) used with insulin can increase the risk of fluid retention and heart failure in susceptible patients; clinicians may monitor for rapid weight gain, edema, or shortness of breath. Corticosteroids, some antipsychotics, and certain HIV therapies can increase glucose. ACE inhibitors and other blood pressure medicines may change glycemic response in some people.

Because interaction details depend on the full medication list, it helps to keep an up-to-date list of prescription drugs, OTC products, and supplements. If a new medicine is started or stopped, clinicians typically reassess glucose patterns rather than making assumptions based on a single reading.

Compare With Alternatives

Basal insulin choices are often based on duration profile, concentration, device preference, prior response, and coverage constraints. Common alternatives include insulin glargine U-100 products, insulin degludec, and insulin detemir (availability varies by country). Even when two medicines share a class, they may not be substitutable without a structured conversion plan.

For example, glargine U-100 (often compared with U-300) is discussed in resources like Lantus Onset And Duration. Comparative discussions can also be found in Toujeo Vs Basaglar and Levemir Vs Lantus Guide, which outline high-level differences that clinicians may consider.

On-site product pages for reference (not a substitute for clinical selection) include Lantus SoloStar Pens and Tresiba FlexTouch Pens. Any switch should be supervised to reduce the risk of hypo- or hyperglycemia during the transition.

Pricing and Access

Access pathways for insulin can depend on insurance status, local dispensing rules, and product availability. The Toujeo Doublestar/Solostar Prefilled Pen may be requested through CanadianInsulin as part of a cross-border, cash-pay prescription access process. US shipping from Canada is handled after prescription documentation is reviewed and accepted for dispensing.

Cash-pay access can help people without insurance. This platform coordinates prescription referral steps and communicates requirements, while dispensing and final clinical checks are completed by licensed pharmacies within their scope of practice. If additional information is required for safety or regulatory reasons, the request may be paused until documentation is complete.

For the smoothest processing, ensure the prescription details match the intended insulin concentration and device format, and confirm your contact information is current. If you are uncertain whether your prescription specifies U-300 versus another concentration, the prescriber should clarify before any change is made.

Authoritative Sources

For decisions about prescribing, dosing, and switching, the official product labeling and clinician guidance should be the primary sources. The links below provide regulator or reference-level information that can support discussions about insulin glargine and concentrated insulin safety.

For additional background on other basal options, a neutral comparison resource is Tresiba Vs Levemir, which describes considerations clinicians may use when selecting long-acting therapy.

• For U.S. regulatory details, see the FDA application overview for Toujeo.
• For consumer-friendly insulin glargine information, review MedlinePlus: insulin glargine.
• For Canadian product records, consult the Health Canada Drug Product Database.

To submit a request, add the item and provide prescription details; approved orders are prepared for prompt, express, cold-chain shipping.

This content is for informational purposes only and is not a substitute for professional medical advice.